230018PsyOmics Quantified Health SolutionClosedProcurementInnovate UKPsyOmics Ltd is a biotech company that is working in collaboration with the Cambridge Centre for Neuropsychiatric Research (CCNR) to deliver improved prevention, diagnosis and treatment of psychiatric conditions. We aim to: (i) Improve treatment by providing contract research services to support clinical trials for psychiatric treatment (ii) Improve diagnosis by developing clinical diagnostics, based on biomarker panels that have been discovered by the Cambridge Centre for Neuropsychiatric Research; and (iii) Improve prevention by providing quantified health solutions that are accessible to everyone, empowering people to understand and improve their own wellbeing and mental health. Of the three areas, prevention has the greatest potential to improve health outcomes. Presently, mental health disorders are usually first picked-up when the associated symptoms are established enough to warrant a visit to the doctor. Consequently, it is often too late for the prevention of the condition. The vast amount of data that can be collected on smart phones, either directly or through health apps or wearable devices such as Fitbit, has huge untapped potential for the detection of the early signs of evolving mental health issues, especially when combined with blood-spot biomarker data. This project intends to deliver a quantified health solution that utilises this data, enabling people to understand their own wellbeing and providing personalised, scientifically validated and quantifiable recommendations that will empower them to take positive action to improve it.